Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma
Clinical trial NCT06749730 · RECRUITING
Trial details
- NCT number
- NCT06749730
- Sponsor
- Henan Cancer Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-01
- Primary completion
- 2026-12-01
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.